secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2026-07-31T21:00:19+00:00
Accession:  0001493152-26-035666
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics effects 1-for-16 reverse stock split to maintain NYSE American listing
--------------------------------------------------------------------------------

- Reverse stock split at 1-for-16 ratio effective July 30, 2026; trading begins July 31 under symbol CLDI.
- Post-split shares outstanding: ~2.45M Common Stock and 9,375 Non-Voting Common Stock.
- Split approved by stockholders on June 12, 2026; no fractional shares issued.
- New CUSIP number 320703 507 assigned to Common Stock.
- Purpose: increase per-share price and support continued listing on NYSE American.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226035666/0001493152-26-035666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226035666/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-035666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer